It has been shown that ICIs are most effective in patients with ‘inflamed tumors’ characterized by PD‐L1 expression, high proportion of tumor‐infiltrating immune cells (TILs), or presence of a strong IFN‐γ cytolytic T‐ cell signature and act by reinvigorating a pre‐existing antitumor T‐cell response [4, 5, 6]. The gene discussed is IFNG; the disease is neoplasm.